DYN · Dyne Therapeutics, Inc.
$18.21
-1.14% last session
End-of-day data · close of 2026-09-11
Market cap
$3B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-5.5
Dividend yield
—
Beta
1.08
Avg volume
3M
Employees
0K
Daily Change %
-1.14%
5 Days Change
-20.96%
10 Days Change
-24.54%
30 Days Change
-28.15%
60 Days Change
-18.06%
Month to Day Change
-23.55%
Year to Day Change
-1.89%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — DYN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-09
Latest call per bank · past 12 months
Morgan Stanley
Overweight$36.00
+95.4% vs priceJP Morgan
Underweight$10.00
-45.7% vs priceRBC Capital
Outperform$30.00
+62.9% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | Morgan Stanley | Maintains | Overweight | $45.00 → $36.00 |
| 2026-09-09 | JP Morgan | Downgrade | Neutral → Underweight | $17.00 → $10.00 |
| 2026-09-09 | RBC Capital | Maintains | Outperform | $35.00 → $30.00 |
| 2026-09-09 | Baird | Maintains | Outperform | $30.00 → $26.00 |
| 2026-07-31 | Morgan Stanley | Maintains | Overweight | $47.00 → $45.00 |
| 2026-07-30 | RBC Capital | Maintains | Outperform | $30.00 → $35.00 |
| 2026-07-23 | Cantor Fitzgerald | Initiates | Overweight | $0.00 |
| 2026-06-26 | TD Cowen | Initiates | Buy | $0.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 18 — oversold territory; selling pressure looks stretched.
- Price vs 50-day MA: Trading 25.9% below the 50-day MA ($24.56).
- Price vs 200-day MA: Trading 8.4% below the 200-day MA ($19.88).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.97) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($12.37) and high ($26.78).
DYN Price Chart
Loading chart for DYN…
Fundamentals
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.